Welcome to our dedicated page for Mirum Pharmaceuticals SEC filings (Ticker: MIRM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Mirum Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Mirum Pharmaceuticals's regulatory disclosures and financial reporting.
Mirum Pharmaceuticals CEO Christopher Peetz exercised stock options for 20,000 shares of common stock at $2.936 per share and sold 20,000 shares in open-market transactions on July 6, 2026 under a Rule 10b5-1 Plan. Following these trades, he holds 196,019 shares directly and 187,500 shares indirectly through The Peetz Family Trust.
Mirum Pharmaceuticals’ chief financial officer Eric Bjerkholt sold 5,000 shares of common stock in open-market transactions. The sales occurred on July 6, 2026 at prices reported between about $121.13 and $124.94 per share, pursuant to a pre-arranged Rule 10b5-1 plan. Following these transactions, he continues to own 42,181 shares directly.
Christopher Peetz submitted a Form 144 reporting a proposed sale of 20,000 shares of Common Stock via a stock option exercise to be executed on 07/06/2026. The filing notes a prior sale of 30,000 shares on 06/01/2026.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice related to 5,000 shares of Common Stock associated with restricted stock dated 09/11/2024. The filing shows a reported sale of 5,000 shares by Eric Bjerkholt on 06/08/2026 with a value listed as $469,073.00.
Mirum Pharmaceuticals SVP and global controller Jolanda Howe reported an open-market sale of 2,721 shares of common stock at $120.00 per share. After the transaction, she directly holds 3,114 shares. The filing notes the sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 18, 2026, indicating it was scheduled in advance rather than timed discretionarily.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a Form 144 disclosing a proposed resale of 2,721 performance shares dated 03/15/2026. The filing also shows a sale by Jolanda Marie Howe of 2,594 common shares on 06/17/2026 for $264,458.30.
Mirum Pharmaceuticals SVP Jolanda Howe reported an open-market sale of 2,594 shares of Common Stock at $101.95 per share. After this transaction, she directly holds 5,835 shares. The filing notes the sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on March 18, 2026, indicating the timing was scheduled in advance.
Mirum Pharmaceuticals, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 15, 2026. As of the April 20, 2026 record date, 60,977,841 shares of common stock were outstanding and entitled to vote.
Stockholders elected three Class I directors—Lon Cardon, William Fairey, and Timothy Walbert—to serve until the 2029 annual meeting and until their successors are duly elected and qualified. Mirum’s stockholders also ratified the selection of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved, on an advisory basis, the compensation of the company’s named executive officers.
Mirum Pharmaceuticals, Inc. director Timothy P. Walbert reported equity awards consisting of restricted stock units and stock options. He received 1,980 restricted stock units, each representing a right to receive one share of common stock, and 3,772 stock options with an exercise price of $101.00 per share.
Both the RSUs and options vest on the first anniversary of the June 15, 2026 grant date, but will in any case be fully vested on the date of Mirum’s 2027 annual stockholder meeting. After these awards, Walbert holds 1,980 RSUs and 3,772 options directly, reflecting compensation-related grants rather than open‑market trades.
Mirum Pharmaceuticals director Lon Cardon received new equity awards as part of his compensation. He was granted 1,980 restricted stock units, each representing the right to receive one share of common stock, and 3,772 stock options with an exercise price of $101.00 per share.
Both the RSUs and options vest on the first anniversary of the June 15, 2026 grant date, and in any event will be fully vested by the company’s 2027 annual stockholder meeting. After these awards, Cardon directly holds 1,980 RSUs and 3,772 options, with no shares bought or sold in this filing.